Moreover, we aimed to investigate whether selective BCR–ABL/JAK2 dual inhibition therapy using nilotinib combined with ruxolitinib could more effectively eliminate imatinib-insensitive LPCs in vitro and in humanized Ph+ALL mice and the underlying molecular mechanisms of this therapy. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.